$0.15
0.00 (-0.20%)
Open$0.15
Previous Close$0.15
Day High$0.16
Day Low$0.15
52W High$2.85
52W Low$0.14
Volume—
Avg Volume4.89M
Market Cap10.03M
P/E Ratio—
EPS$-1.81
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+4,791.5% upside
Current
$0.15
$0.15
Target
$7.44
$7.44
$4.65
$7.44 avg
$8.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.30M | 4.98M | 4.38M |
| Net Income | -11,481 | -9,902 | -8,948 |
| Profit Margin | -0.2% | -0.2% | -0.2% |
| EBITDA | -10,930 | -11,209 | -8,630 |
| Free Cash Flow | -9,428 | -11,072 | -6,340 |
| Rev Growth | +3.9% | +11.7% | +7.6% |
| Debt/Equity | 0.42 | 0.41 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |